PE82899A1 - INHIBIDORES DE LA FARNESIL TRANSFERASA COMBINADOS CON INHIBIDORES DE LA HMG CoA REDUCTASA PARA EL TRATAMIENTO DEL CANCER - Google Patents
INHIBIDORES DE LA FARNESIL TRANSFERASA COMBINADOS CON INHIBIDORES DE LA HMG CoA REDUCTASA PARA EL TRATAMIENTO DEL CANCERInfo
- Publication number
- PE82899A1 PE82899A1 PE1998000500A PE00050098A PE82899A1 PE 82899 A1 PE82899 A1 PE 82899A1 PE 1998000500 A PE1998000500 A PE 1998000500A PE 00050098 A PE00050098 A PE 00050098A PE 82899 A1 PE82899 A1 PE 82899A1
- Authority
- PE
- Peru
- Prior art keywords
- halo
- alkyl
- coa reductase
- hmg coa
- optionally replaced
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE LA ENZIMA FARNESIL TRANSFERASA (FTASA) COMO a)UN COMPUESTO (I), DONDE R1 Y R2 SON -(CH2)p(HETEROCICLO DE 5-10 MIEMBROS), ALILO: OPCIONALMENTE SUSTITUIDOS POR 1-3 R9 o HALO; p ES 0-3; R3 ES -(CH2)m(1- o 2-ADAMANTILO), -(CH2)m(CICLOALQUILO C3-C10), ENTRE OTROS; m ES 0-6; R4 ES ARILO C6-C10, HETEROCICLO DE 5-10 MIEMBROS O ALQUILO C1-C6; OPCIONALMENTE SUSTITUIDOS POR 1-3 R5; R5 ES HALO, SO2NR6R7, NR6R8, ENTRE OTROS; R6 Y R7 SON H o ALQUILO C1-C4; R8 ES R6 U -OR6; b)COMPUESTOS IIA Y IIB, DONDE R1 ES H, HALO, CN, ENTRE OTROS; R2 ES -(CH2)nY U -OCOR5; R3 ES PIRIDILO, PIRIMIDILO, ENTRE OTROS; Y ES H, OH, NH2, ENTRE OTROS; R5 ES ALQUILO C1-C4, FENILO O BENCILO OPCIONALMENTE SUSTITUIDO; W ES HALO, R5, OH, ENTRE OTROS; m ES 0-2; n ES 1-7; p ES 0-1; E1 Y E2 SON H, HALO, ALQUILO C1-C3, ENTRE OTROS; HET` Y HET'' SON HETEROCICLOS DE 6 MIEMBROS CON 1-4 N, SUSTITUIDOS OPCIONALMENTE. LA COMPOSICION COMPRENDE TAMBIEN UN INHIBIDOR DE HIDROXIMETILGLUTARIL COENZIMA A REDUCTASA (HMG CoA REDUCTASA) SELECCIONADO DE ATORVASTATINA, PRAVASTATINA, LOVASTATINA, ENTRE OTROS. LA COMPOSICION INHIBE EL DESARROLLO ANORMAL DE CELULAS POR LO QUE PUEDE SER UTIL EN EL TRATAMIENTO DEL CANCER O TRASTORNO PROLIFERATIVO BENIGNO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4963897P | 1997-06-16 | 1997-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE82899A1 true PE82899A1 (es) | 1999-08-26 |
Family
ID=21960890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998000500A PE82899A1 (es) | 1997-06-16 | 1998-06-12 | INHIBIDORES DE LA FARNESIL TRANSFERASA COMBINADOS CON INHIBIDORES DE LA HMG CoA REDUCTASA PARA EL TRATAMIENTO DEL CANCER |
Country Status (37)
| Country | Link |
|---|---|
| EP (1) | EP0986387B1 (es) |
| JP (1) | JP3713051B2 (es) |
| KR (1) | KR100392573B1 (es) |
| CN (1) | CN1259868A (es) |
| AP (1) | AP9801261A0 (es) |
| AR (1) | AR013090A1 (es) |
| AT (1) | ATE235905T1 (es) |
| BG (1) | BG103946A (es) |
| BR (1) | BR9810616A (es) |
| CA (1) | CA2294399C (es) |
| CO (1) | CO4950607A1 (es) |
| DE (1) | DE69812933T2 (es) |
| DK (1) | DK0986387T3 (es) |
| DZ (1) | DZ2518A1 (es) |
| EA (1) | EA199901043A1 (es) |
| ES (1) | ES2196559T3 (es) |
| GT (1) | GT199800081A (es) |
| HN (1) | HN1998000091A (es) |
| HR (1) | HRP980328B1 (es) |
| HU (1) | HUP0004624A3 (es) |
| ID (1) | ID23014A (es) |
| IL (1) | IL132765A0 (es) |
| IS (1) | IS5259A (es) |
| MA (1) | MA24569A1 (es) |
| NO (1) | NO996206L (es) |
| NZ (1) | NZ500662A (es) |
| OA (1) | OA11231A (es) |
| PA (1) | PA8453601A1 (es) |
| PE (1) | PE82899A1 (es) |
| PL (1) | PL337651A1 (es) |
| PT (1) | PT986387E (es) |
| SK (1) | SK169699A3 (es) |
| TN (1) | TNSN98088A1 (es) |
| TR (1) | TR199903074T2 (es) |
| UA (1) | UA57081C2 (es) |
| WO (1) | WO1998057633A1 (es) |
| ZA (1) | ZA985182B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA003860B1 (ru) * | 1998-05-12 | 2003-10-30 | Варнер-Ламберт Компани | КОМБИНАЦИИ ИНГИБИТОРОВ ПРОТЕИН ФАРНЕЗИЛТРАНСФЕРАЗЫ И HMG KoA РЕДУКТАЗЫ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА |
| AU6256499A (en) * | 1998-09-24 | 2000-04-10 | Merck & Co., Inc. | A method of treating cancer |
| EP1006113A1 (en) * | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
| AU4988100A (en) * | 1999-05-07 | 2000-11-21 | Brigham And Women's Hospital | Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| CA2432137C (en) | 2000-12-19 | 2010-12-21 | Pfizer Products Inc. | Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production |
| DE60122939T2 (de) | 2000-12-21 | 2007-01-11 | Nitromed, Inc., Bedford | Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren |
| US20020151563A1 (en) * | 2001-03-29 | 2002-10-17 | Pfizer Inc. | Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth |
| US6740757B2 (en) | 2001-08-29 | 2004-05-25 | Pfizer Inc | Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer |
| TWI297606B (en) * | 2004-01-16 | 2008-06-11 | Nat Health Research Institutes | Cancer therapy |
| US8168667B2 (en) | 2006-05-31 | 2012-05-01 | Galapagos Nv | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such |
| GB2463514C (en) | 2008-09-11 | 2018-09-26 | Galapagos Nv | Imidazolidine compounds and uses therefor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0856315B1 (en) * | 1995-08-09 | 2005-08-24 | Banyu Pharmaceutical Co., Ltd. | Protein-farnesyltransferase inhibitors in combination with hmgcoa-reductase-inhibitors for the treatment of aids |
-
1998
- 1998-05-06 UA UA99126842A patent/UA57081C2/uk unknown
- 1998-06-05 BR BR9810616-3A patent/BR9810616A/pt not_active Application Discontinuation
- 1998-06-05 ID IDW991597A patent/ID23014A/id unknown
- 1998-06-05 JP JP50403099A patent/JP3713051B2/ja not_active Expired - Fee Related
- 1998-06-05 NZ NZ500662A patent/NZ500662A/en unknown
- 1998-06-05 WO PCT/IB1998/000881 patent/WO1998057633A1/en not_active Application Discontinuation
- 1998-06-05 PL PL98337651A patent/PL337651A1/xx unknown
- 1998-06-05 AT AT98921688T patent/ATE235905T1/de not_active IP Right Cessation
- 1998-06-05 IL IL13276598A patent/IL132765A0/xx unknown
- 1998-06-05 TR TR1999/03074T patent/TR199903074T2/xx unknown
- 1998-06-05 EA EA199901043A patent/EA199901043A1/ru unknown
- 1998-06-05 DK DK98921688T patent/DK0986387T3/da active
- 1998-06-05 CA CA002294399A patent/CA2294399C/en not_active Expired - Fee Related
- 1998-06-05 KR KR10-1999-7011860A patent/KR100392573B1/ko not_active IP Right Cessation
- 1998-06-05 ES ES98921688T patent/ES2196559T3/es not_active Expired - Lifetime
- 1998-06-05 SK SK1696-99A patent/SK169699A3/sk unknown
- 1998-06-05 PT PT98921688T patent/PT986387E/pt unknown
- 1998-06-05 EP EP98921688A patent/EP0986387B1/en not_active Expired - Lifetime
- 1998-06-05 DE DE69812933T patent/DE69812933T2/de not_active Expired - Fee Related
- 1998-06-05 HU HU0004624A patent/HUP0004624A3/hu unknown
- 1998-06-05 CN CN98805968A patent/CN1259868A/zh active Pending
- 1998-06-09 HN HN1998000091A patent/HN1998000091A/es unknown
- 1998-06-11 AP APAP/P/1998/001261A patent/AP9801261A0/en unknown
- 1998-06-12 AR ARP980102812A patent/AR013090A1/es unknown
- 1998-06-12 PE PE1998000500A patent/PE82899A1/es not_active Application Discontinuation
- 1998-06-15 DZ DZ980128A patent/DZ2518A1/xx active
- 1998-06-15 GT GT199800081A patent/GT199800081A/es unknown
- 1998-06-15 TN TNTNSN98088A patent/TNSN98088A1/fr unknown
- 1998-06-15 PA PA19988453601A patent/PA8453601A1/es unknown
- 1998-06-15 ZA ZA9805182A patent/ZA985182B/xx unknown
- 1998-06-15 MA MA25114A patent/MA24569A1/fr unknown
- 1998-06-16 HR HR980328A patent/HRP980328B1/xx not_active IP Right Cessation
- 1998-06-16 CO CO98034148A patent/CO4950607A1/es unknown
-
1999
- 1999-11-19 IS IS5259A patent/IS5259A/is unknown
- 1999-12-03 BG BG103946A patent/BG103946A/bg unknown
- 1999-12-10 OA OA9900276A patent/OA11231A/en unknown
- 1999-12-15 NO NO996206A patent/NO996206L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE82899A1 (es) | INHIBIDORES DE LA FARNESIL TRANSFERASA COMBINADOS CON INHIBIDORES DE LA HMG CoA REDUCTASA PARA EL TRATAMIENTO DEL CANCER | |
| TR200101339T2 (tr) | Potasyum kanal modülatörleri olarak 3-yer-alanlı-4-arilkinolin-2-on türevleri, 3,4-okzadiazolon türevleri | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| ATE464287T1 (de) | Cyclohexyl-sulphone als gamma-sekretase- inhibitoren | |
| BR9912073A (pt) | Composições farmacêuticas que compreendem 2-quinolonas | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| TR200201509T2 (tr) | Farmasötik olarak aktif benzazol türevleri. | |
| BR0309606A (pt) | Hidrolisados de mercaptosilano bloqueado como agentes de acoplamento para composições elastoméricas carregadas com minerais | |
| PE20010544A1 (es) | Derivados de mutilina utiles como agentes antibacterianos | |
| PE20050730A1 (es) | Derivados de 2,5-dihidropirrol 2,2-disustituidos como inhibidores de quinesinas mitoticas | |
| MX2007013065A (es) | Derivados de dihidrobenzofurano y usos de los mismos. | |
| DE60328010D1 (de) | Heterocyclische verbindungen | |
| MX9301032A (es) | Compuestos farmaceuticos y procedimento para su preparacion | |
| GEP20074210B (en) | Tropane derivatives as ccr5 modulators | |
| ATE377001T1 (de) | Pleuromutilinderivate als antimikrobielle mittel | |
| GT199900154A (es) | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas. | |
| BRPI0408338A (pt) | piperidinas substituìdas como novos inibidores de mdm2-p53 | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| DE69231298T2 (de) | Substituierte Dibenzoxazepinverbindungen, pharmazeutische Zusammensetzungen und Anwendungsmethoden | |
| PE20090357A1 (es) | Compuestos heterociclicos con actividad sobre los receptores muscarinicos m3 | |
| DE69713273D1 (de) | Verwendung von 3,4-Diphenylchromanen zur Herstellung eines Arzneimittels zur Behandlung bzw. Vorbeugung des Prostatakarzinoms | |
| PE79599A1 (es) | Derivados de 5'-desoxicitidina | |
| PE20060103A1 (es) | Nuevas 5-acilindolinonas con contenido en cicloalquilo y su preparacion como medicamento | |
| AR018162A1 (es) | Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica | |
| MY124078A (en) | Eletriptan hydrobromide monohydrate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |